Oteseconazole for Recurrent Vulvovaginal Candidiasis - An Insight

Overview:

Oteseconazole was shown to have higher mycological and clinical cure rates than Fluconazole. Generally, the drug is well-tolerated with few adverse effects. This is a safe alternative for managing RVVCs based on efficacy and its safety profile. In April 2022, the United States Food and Drug Administration (FDA) approved Oteseconazole to manage recurrent vulvovaginal candidiasis. FDA approval of Oteseconazole is based on positive clinical trial results.

Drug Group:

Oteseconazole is an azole, a class of antifungal drugs. This chemical selectively inhibits fungal CYP51, which plays an important role in the growth and maintenance of the fungal cell membrane. Due to its low affinity for human CYP (Cytochrome P450)enzymes, Oteseconazole is formulated specially to make it effective and safe for treating fungal diseases such as RVVC.

Dosages:

• Adults or Preteen Girls Who Have Started Their Menstrual Cycle: Oteseconazole dose is 600 mg(milligrams) as one dose on day 1 and 450 mg as one on day 2. Then 150 mg once a week every seven days from day 14 for 11 weeks (weeks 2 to 12).

• Children: It is up to the doctor to decide on the dosage and usage.

For Patients:

What Is Recurrent Vulvovaginal Candidiasis?

Women with four or more episodes of vulvovaginal cancers in a year are said to have RVVC. Candida albicans or other Candida species bring about RVVC and considerably adversely impact the quality of life. It affects several million women of childbearing age worldwide and is most common in the 25 to 34 age group. There are few therapeutic options, and while maintenance therapy will ease symptoms, any hope of getting the condition completely cured is poor. In managing RVVC, what needs to be explored are the immune mechanisms, genetic factors that come into play, and efficient treatments involving vaccines.

What Is the Management of Recurrent Vulvovaginal Candidiasis?

Management of RVVC is challenging. Symptoms are poorly eradicated, but symptom suppression with maintenance therapy with Fluconazole is effective. Vaccination and species-targeted treatment are urgently needed. No evidence supports that lactobacillus, yogurt, vinegar, garlic, Chinese medicine, and tea tree oil are alternative medications. Oral Fluconazole once a week for six months may be helpful, although other regimens may be more effective. Other nonpharmacologic therapies include dietary modifications and wearing cotton underwear. Many treatment plans are individualized due to the lack of available data.

How Does Oteseconazole Work?

Oteseconazole exerts a selective inhibiting action on fungal lanosterol demethylase, an important enzyme for fungal growth. This enzyme inhibition prevents ergosterol synthesis, one of the main components in the fungal cell membrane. The disruption leads to fungal cell death, enhanced cellular permeability, decreased yeast production, and cessation of endogenous respiration. Teseconazole is efficient in recurrent vulvovaginal candidiasis treatment by preventing acute episodes and lowering recurrence rates.

What Are the Benefits of Using Oteseconazole for Recurrent Vulvovaginal Candidiasis?

• Efficacy: Oteseconazole is effective in preventing and treating RVVC. The phase 3 clinical trial treated acute VVC similarly to Fluconazole and prevented RVVC significantly more effectively than a placebo.

• Less Frequency: A comprehensive review and meta-analysis found that Oteseconazole was associated with a significantly reduced incidence of RVVC through week 48.

• Mild Consequences: Among the adverse effects reported, 66.2 percent were mild, and 31.2 percent were moderate, indicating that most adverse effects caused fewer complications.

What Must the Patient Inform the Doctor Before Taking Oteseconazole?

Before starting Oteseconazole, a patient should inform a physician if they have a history of kidney or liver disease or are currently suffering from it. Oteseconazole must not be used in people who are breastfeeding a baby, pregnant, or can become pregnant. A patient must inform the health expert about their medical history before starting the treatment with Oteseconazole.

What Are the Side Effects of Using Oteseconazole?

Oteseconazole side effects are as follows:

• Painful urination with a burning sensation.

• Painful or difficult urination.

• Copious vaginal bleeding.

• Hot flushes.

• Longer or heavier menstrual periods.

For Doctors:

Description:

Oteseconazole Tablets contain Oteseconazole, an oral azole antifungal drug.

The chemical name for Oteseconazole is (R)-2-(2,4-difluorophenyl).1,1-difluoro-3-(tetrazol-1-yl)(4-(2,2,2-trifluoroethoxy)phenyl) pyridin-2-yl2-Pyridineethanol, propan-2-ol, α-(2,4-difluorophenyl)-β bisfluoro-α-(1H-tetrazol-1-ylmethyl)-5-(4-trifluoroethoxy)phenyl (2,2,2)-,(αR)-. The empirical formula used is C23H16F7N5O2. The molecular weight is 527.39 g/mol(gram per mole).

Oteseconazole is a white or light-colored crystalline powder, having wide solubility in organic solvents but is practically insoluble in water within the pH range of 1 to 9.

Oteseconazole capsules are oral capsules, each containing 150 mg of Oteseconazole phosphate, equivalent to 125 mg of Oteseconazole. The formulation's inactive ingredients are lactose, magnesium stearate, silicified microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, and sodium lauryl sulfate. The formulation does not contain grain-derived gluten-containing ingredients such as rye, barley, or wheat.

Therapeutic Uses of Oteseconazole:

Oteseconazole is indicated for the treatment of RVVC in an infertile female. Compared with placebo and Fluconazole, Oteseconazole has demonstrated higher efficacy in reducing the incidence of RVVC and at a lower rate of acute recurrence of VVC. Since Oteseconazole has effectively achieved both mycological and clinical cures, it may be considered one of the therapeutic options for severe infection of vulvovaginal candidiasis.

Dosage Forms and Strengths:

Oteseconazole150 is debossed in black ink on lavender hard gelatin capsules containing 150 mg of Oteseconazole. The carton does not contain Fluconazole.

Dosage Regimen for Oteseconazole only:

• Day 1: Administer Oteseconazole 600 mg (as a single dose), then.

• Day 2: Administer Oteseconazole 450 mg (as a single dosage), then.

• Start on Day 14 and administer Oteseconazole 150 mg once a week.

Indications:

Oteseconazole is indicated for the treatment of RVVC in women who are not reproductive viable. It has been more effective, compared with Fluconazole and placebo, at reducing the incidence of RVVC and recurrence of acute vulvovaginal candidiasis. The effectiveness of Oteseconazole in achieving both mycological and clinical cure makes it a valued treatment option for severe vulvovaginal candidiasis.

Contradictions:

Oteseconazole is contraindicated in pregnant women and nursing mothers, patients who desire pregnancy, and patients with liver or renal disease. It should only be used by nonpregnant women who cannot become pregnant.

Precautions:

Embryo-Fetal Toxicity: Animal studies suggest that Oteseconazole is harmful to a fetus. The approximately 690-day drug exposure window, based on a five-times half-life of Oteseconazole, prevents sufficient reduction of the hazards associated with embryo-fetal harm. Advise patients that because of the potential risks to a fetus or breastfed infant, Oteseconazole is not indicated for use in women who are pregnant or nursing or in women who may become pregnant.

What Are the Adverse Reactions of Oteseconazole?

• Indigestion.

• Heartburn.

• Belching.

• Sour or acid stomach.

• Nausea.

• Unsettled, painful, or uncomfortable stomach.

What Are the Pharmacological Aspects of Oteseconazole?

Mechanism of Action:

Oteseconazole mechanism of actionis an azole metalloenzyme inhibitor that targets 14α demethylase (CYP51), a fungal sterol essential for the development and integrity of fungal cell membranes. This enzyme catalyzes an early step in the biosynthesis route of ergosterol. Some of the 14-methylated sterols that accumulate due to CYP51 inhibition are toxic to fungus. The tetrazole metal-binding group gives Oteseconazole a decreased affinity for human CYP enzymes.

Pharmacodynamics:

Regarding curing severe vulvovaginal candidiasis, Oteseconazole outperformed Fluconazole regarding mycological and clinical improvements. Over 48 weeks, Oteseconazole outperformed a placebo in avoiding the recurrence of RVVC. Teseconazole outperformed a placebo in the maintenance phase at preventing bouts of acute vulvovaginal candidiasis. Compared to Fluconazole, Oteseconazole treatment enhanced the percentage of individuals who achieved both a mycological and clinical cure. RVVC can be effectively and safely managed with Oteseconazole.

Pharmacokinetics:

Oteseconazole is characterized by an apparent volume of distribution of 0.7 L/kg (liter per kilogram) and a moderate plasma protein binding of 12 percent. The drug is well-tolerated, and studies demonstrate that it is more effective than a placebo for up to 50 weeks of preventive maintenance and not inferior to Fluconazole in acute treatment. Over 48 weeks of use, Oteseconazole has been found more effective in preventing the recurrence of RVVC than placebo. Oteseconazole is approved for this indication.

Dosage: Recommended dosages for Oteseconazole are 600 mg taken orally as a single dose on day 1, 450 mg on day 2, and 150 mg taken orally once a week for 11 weeks.

Drug Interactions:

• Pitavastatin.

• Alpelisib.

• Atorvastatin.

• Chlorothiazide.

• Cimetidine.

• Daunorubicin.

• Dipyridamole.

• Doxorubicin,

• Ethinylestradiol.

• Fluvastatin.

• Glyburide.

• Imatinib.

• Irinotecan.

• Lapatinib.

• Ledipasvir/sofosbuvir.

• Leflunomide.

• Lenvatinib.

• Methotrexate.

• Mitoxantrone.

• Nitrofurantoin.

• Osimertinib.

• Ozanimod.

• Pantoprazole.

• Pazopanib.

• Riociguat.

• Selexipag.

• Selumetinib.

• Sofosbuvir.

• Sulfasalazine.

• Talazoparib.

• Tenofovir AF.

• Tenofovir DF.

• Topotecan.

• Ubrogepant.

• Velpatasvir.

• Vemurafenib.

• Voclosporin.

• Voxilaprevir.

Use In Specific Populations:

• Pregnancy and Lactation: Pregnancy is a contraindication for the treatment with Oteseconazole, for it may cause harm to the unborn child. It should not be used by pregnant ladies or those who will become pregnant. It is specially indicated in non-pregnant women or women who cannot conceive. Thus, if individuals are lactating or may become pregnant, Oteseconazole is strictly contraindicated.

• Pediatrics: The safety and efficacy of Oteseconazole in pediatric patients have yet to be researched.

• Geriatrics: The safety and efficacy of Oteseconazole in adults older than 65 years is not yet established.

Clinical Studies:

Two trials, 1 and 2, are placebo-controlled, multicenter, and included 656 adults and postmenarchal juvenile females with RVVC (defined as ≥3 episodes of vulvovaginal candidiasis [VVC] in 12 months). In a multicenter, double-blind experiment, 219 adults and postmenarchal pediatric females with RVVC were randomized. Oteseconazole is not indicated in reproductively viable females due to the risk of embryo-fetal harm, although clinical efficacy was derived from a population that included females of reproductive potential.

Both trials involved a two-phase study: an 11-week maintenance period and an open-label induction phase. Patients received three consecutive doses of 150 mg Fluconazole during the induction phase every 72 hours on Days 1, 4, and 7. In the maintenance period, patients were randomized 2:1 either to 150 mg of Oteseconazole or to placebo for seven days, then for eleven weeks. If the acute VVC episode was resolved, it was defined as a vulvovaginal signs and symptoms score of less than 3. This was repeated 14 days following the initial dose of Fluconazole.

Patients were randomized to either Oteseconazole or placebo in two comparative trials for maintenance following Fluconazole administered during induction. A total of 326 of 483 patients from Study 1 who were in the induction phase went on to be in maintenance. Similarly, 330 of the 425 individuals included in Study 2 went on to get maintenance. Efficacy was defined as the number of patients who developed at least one acute episode of VVC, as confirmed by culture during the Maintenance Phase through Week 48. Clinical signs and symptoms included erythema, edema, excoriation, itching, burning, and irritation. Patients' age bracket ranged between 18 and 44 years, with a mean of 34 years. The age brackets were between 17 and 78 years. The study involved ethnic differences.

The efficacy of both Trials 1 and 2 was based on the proportion of patients with at least one culture-confirmed acute VVC episode [a positive fungal culture for Candida species with a clinical signs and symptoms score of three or above] during the Maintenance Phase through Week 48. The clinical signs and symptoms assessed included erythema, edema, excoriation, itching, burning, and irritation. Since all patients with a signs and symptoms score of at least three and a positive KOH test could be treated for acute VVC if clinically necessary, the percentage of patients with at least one culture-verified acute VVC episode was calculated.